BTLA inhibitor plus toripalimab and chemo before & after esophagus surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a new immunotherapy drug (JS004), another immunotherapy (toripalimab), and chemotherapy before and after surgery for people with a certain type of locally advanced esophageal cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that is locally advanced (spread to nearby lymph nodes but not to other organs).
- You have not had any previous treatment for esophageal cancer, such as chemotherapy, radiation, or immunotherapy.
- Your blood counts, liver, and kidney function are within a certain healthy range.
- You are willing to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of targeted therapy (anlotinib), immunotherapy (toripalimab), and chemotherapy given before surgery for esophageal cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This trial tests a drug called Toripalimab given after surgery for esophageal cancer to see if it helps prevent the cancer from coming back. It's for people who already had chemotherapy and immunotherapy before surgery and had all the cancer removed.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.